QR Kod

DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger

IntroductionFluoropyrimidines (FP) are the mainstay of colorectal cancer (CRC) treatment, but can cause severe toxicity in up to 40% of patients. Variants in the DPYD gene are associated with these adverse events. A DPYD-guide dose adjustment is now recommended in Europe. This ambispective study aim...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Rocío Rosas-Alonso, Nuria Rodríguez Salas, Pablo Perez Wert, Angela Hoyo, Susana Martin-López, Daniel Martínez-Pérez, Iciar Ruiz-Gutiérrez, Diego Jiménez-Bou, Jesús Peña, Pedro Arias, Ana Custodio, Itsaso Losantos-García, Alberto M. Borobia, Jaime Feliu, Ismael Ghanem
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2025-09-01
Seri Bilgileri:Frontiers in Pharmacology
Konular:
fluoropyrimidines
DPYD
colorectal cancer
toxicity
discontinuation
Online Erişim:https://www.frontiersin.org/articles/10.3389/fphar.2025.1645188/full
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller